Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ganten, TM; Stauber, RE; Schott, E; Malfertheiner, P; Buder, R; Galle, PR; Göhler, T; Walther, M; Koschny, R; Gerken, G.
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Clin Cancer Res. 2017; 23(19):5720-5728
Doi: 10.1158/1078-0432.CCR-16-0919
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Stauber Rudolf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose: Sorafenib is the only currently approved systemic therapy for advanced hepatocellular carcinoma (HCC). We aimed to evaluate the safety and efficacy of sorafenib therapy in patients with HCC under real-life conditions regarding patient, tumor characteristics, and any adverse events at study entry and at follow-up visits every 2 to 4 months.Experimental Design: The current INSIGHT study is a noninterventional, prospective, multicenter, observational study performed in 124 sites across Austria and Germany between 2008 and 2014.Results: Median overall survival and time to progression (RECIST) were found to be dependent on baseline Barcelona Clinic Liver Cancer (BCLC) tumor stage (A: 29.2, B: 19.6, C: 13.6, D: 3.1 and A: 6.0, B: 5.5, C: 3.9, and D: 1.7 months, respectively), Child-Pugh liver function (A: 17.6, B: 8.1, C: 5.6 and A: 5.3, B: 3.3, C: 2.5 months, respectively), and performance status of the patient; however, age did not affect prognosis. Sorafenib-related adverse events at any grade occurred in 64.9% of patients, with diarrhea (35.4%), hand-foot-skin reaction (16.6%), nausea (10.3%), and fatigue (11.2%) occurring most frequently.Conclusions: Sorafenib treatment was shown to be effective in a real-life setting, in agreement with previously reported clinical trial data. The therapy was found to have an acceptable safety profile, with predominantly mild to moderate side effects. Clin Cancer Res; 23(19); 5720-8. ©2017 AACR. ©2017 American Association for Cancer Research.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Carcinoma, Hepatocellular - drug therapy
- Carcinoma, Hepatocellular - pathology
- Disease Progression -
- Disease-Free Survival -
- Drug-Related Side Effects and Adverse Reactions - pathology
- Female -
- Humans -
- Liver Neoplasms - drug therapy
- Liver Neoplasms - pathology
- Male -
- Middle Aged -
- Neoplasm Staging -
- Niacinamide - administration & dosage
- Niacinamide - adverse effects
- Niacinamide - analogs & derivatives
- Phenylurea Compounds - administration & dosage
- Phenylurea Compounds - adverse effects
- Prognosis -
- Protein Kinase Inhibitors - administration & dosage
- Protein Kinase Inhibitors - adverse effects
- Sorafenib -